The US Bankruptcy Court gave an order approving the sale of certain assets of Immune Pharmaceuticals, Inc on October 21, 2019. The debtor has been authorized to sell its certain assets to Alexion Pharmaceuticals, Inc., for a purchase price of $6 million in cash. The debtor’s assets include Anti-Eotaxin Assets. At the auction held, Alexion Pharmaceuticals, Inc. emerged as the winning bidder by offering a purchase price of $6 million.